Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$23.78M |
$1.31
-4.71%
|
|
STCB
Starco Brands, Inc.
Vertical integration via acquisition of The Starco Group provides contract manufacturing capabilities.
|
$23.53M |
$0.03
|
|
MRKR
Marker Therapeutics, Inc.
Marker Therapeutics develops MAR-T cell therapies, a cell-based immunotherapy platform targeting cancer.
|
$23.42M |
$1.81
+3.12%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$22.89M |
$20.55
+2.04%
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$22.43M |
$0.94
+1.16%
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$21.50M |
$1.71
-1.16%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$20.52M |
$1.00
+0.76%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$20.37M |
$0.66
-1.07%
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$20.35M |
$0.28
-31.68%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Directly aligned with LIMN's focus on cancer therapies (anti-CD47 antibody) within the biotech-oncology space.
|
$20.01M |
$0.75
-3.68%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$19.52M |
$0.58
+1.41%
|
|
CVM
CEL-SCI Corporation
Direct product category for CEL-SCI's lead immunotherapy for cancer (Multikine) under oncology biotech.
|
$19.30M |
$6.07
-4.64%
|
|
INTS
Intensity Therapeutics, Inc.
Company develops oncology-focused therapeutics (INT230-6.00) and operates in Biotech - Oncology.
|
$19.21M |
$0.41
-1.70%
|
|
MDXH
MDxHealth S.A.
GPS test provides biomarker-based risk stratification that informs treatment decisions, aligning with Companion Diagnostics.
|
$19.01M |
$3.85
+3.91%
|
|
BCAB
BioAtla, Inc.
Oz-V and Mec-V are ADCs (CAB-ROR2-ADC, CAB-AXL-ADC) - major product modality.
|
$18.92M |
$0.33
+3.25%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$18.91M |
$2.17
-0.69%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$18.63M |
$8.62
-1.54%
|
|
KAPA
Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharma focused on oncology therapies, including immunotherapies and cell therapies.
|
$18.10M |
$0.87
-1.96%
|
|
ALLR
Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
|
$17.25M |
$1.18
-0.42%
|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$17.18M |
$1.47
-6.37%
|
|
SIGY
Sigyn Therapeutics, Inc.
Company’s cancer-related therapeutic platform focus places it in Biotech - Oncology.
|
$17.09M |
$0.50
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$17.07M |
$10.98
+0.32%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$16.86M |
$0.72
-1.07%
|
|
OSRH
OSR Holdings, Inc.
VAXIMM's lead oncology immunotherapy candidate positions OSRH in the Biotech - Oncology space.
|
$16.13M |
$0.75
-4.54%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$16.11M |
$8.11
-1.10%
|
|
DSY
Big Tree Cloud Holdings Limited
Provides OEM/ODM manufacturing services, i.e., contract manufacturing for others.
|
$16.07M |
$0.28
+0.14%
|
|
COSM
Cosmos Health Inc.
Owns/operates in-house EU GMP manufacturing via Cana Laboratories Holdings Cyprus Ltd. and Cana S.A., enabling contract manufacturing revenue.
|
$15.85M |
$0.53
-2.47%
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$15.20M |
$0.33
+3.70%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
LB-100 is Lixte's lead oncology drug candidate (PP2A inhibitor) being developed for cancer therapy, constituting the primary product/offerable asset.
|
$15.14M |
$3.33
-2.35%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 is an orally administered small molecule therapeutic, matching the Oral Small Molecule Therapeutics tag.
|
$15.14M |
$1.67
-4.86%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$14.84M |
$0.95
-8.64%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$14.60M |
$0.84
-1.35%
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
APLT
Applied Therapeutics, Inc.
Applied Therapeutics is a biotech focused on rare diseases, with lead programs in rare metabolic/neurologic conditions (e.g., govorestat for CMT-SORD) and out-licensing efforts in rare disease assets.
|
$14.44M |
$0.09
-7.36%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$14.44M |
$0.57
-0.04%
|
|
ALUR
Allurion Technologies Inc.
Drug delivery platform angle via GLP-1 drug-eluting intragastric balloon; joint development.
|
$14.36M |
$1.84
-2.65%
|
|
TRAW
Traws Pharma, Inc.
Company is developing Antiviral Small-Molecule Therapeutics (ratutrelvir) for COVID-19 as a core antiviral program.
|
$14.27M |
$2.01
+16.86%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$14.03M |
$0.35
+3.02%
|
|
TPST
Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
|
$13.81M |
$3.15
-0.16%
|
|
HOTH
Hoth Therapeutics, Inc.
BioLexa platform and HT-001 formulation imply a drug delivery platform approach (localized/topical delivery).
|
$13.79M |
$1.04
-3.24%
|
Showing page 21 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
